List view / Grid view
3 September 2015 | By Victoria White
The deals market for antisense RNAi therapeutics witnessed a record year in 2014, with a total value of almost $5.6 billion across 59 transactions...
15 June 2015 | By Victoria White
Researchers have found that modulation of B lymphocyte function may be a means of regulating T lymphocyte function to treat immune-mediated disorders...
18 March 2015 | By Victoria White
TxCell SA has announced that a key patent, covering its lead product Ovasave(R) in IBD, is to be granted in the US on 31 March 2015...
26 February 2015 | By TxCell
TxCell invited to speak at largest US meeting for investors in emerging growth companies...
26 February 2015 | By MSD
Expansion in treatment options for moderately to severely active disease allows patients access to REMICADE® (infliximab), SIMPONI® (golimumab) and Humira® (adalimumab)...
25 February 2015 | By Mundipharma
Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets...
23 February 2015 | By Celltrion Healthcare
Cost savings could help improve patient access to life-changing treatment...
5 February 2015 | By TxCell
TxCell, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, reports its revenues as of December 31, 2014 and updates on forthcoming milestones...
29 January 2015 | By TxCell
Milestone payment triggered by first patient enrolment in the phase IIb clinical trial for refractory Crohn’s disease...
27 January 2015 | By TxCell
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces the receipt of EUR 1.7 million from Bpifrance...
8 January 2015 | By Advanced Accelerator Applications S.A.
Advanced Accelerator Applications S.A. announced that it has acquired the remaining 49.9% of Atreus Pharmaceuticals Corporation, a development-stage biopharmaceutical company headquartered in Ottawa, Canada...
8 January 2015 | By MSD
NICE says ‘yes’ to REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab) for adult patients with moderately to severely active ulcerative colitis...
6 January 2015 | By TxCell
TxCell SA (FR0010127662 – TXCL) announces that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis...
12 November 2014 | By Enterome
Collaboration to generate novel diagnostic products to support personalized therapies for microbiome-related diseases...
28 October 2014 | By TxCell
TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease...
